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1. Introduction 
Renal transplantation improves survival of patients with end-stage kidney disease (ESKD) 
(Wolfe, McCullough et al. 2009). In most countries, including the United States and 
Australia, there continues to be a growing disparity between the limited availability of 
deceased-donor kidneys compared to potential transplant candidates.  In contrast, live-
donor kidney transplantation has been steadily increasing over time. It has been well 
established that the type (live or deceased donor kidneys) and quality (donor age and 
presence of donor comorbidities) of donor kidneys have a significant impact on renal 
allograft outcomes. In this chapter, we will focus on both live-donor and deceased donor 
kidney transplantation and the impact of donor factors and types on graft and patient 
outcomes. With the continuing shortage of deceased donor kidneys coupled with a growing 
number of older transplant candidates, there has been a greater acceptance of using older 
donor kidneys, including increased utility of expanded criteria donor (ECD) and donation 
after cardiac death (DCD) kidneys. We will look at the impact of using ECD and DCD 
kidneys on graft and patient survival, and to identify modifiable factors that may improve 
transplant outcomes in recipients receiving ECD and DCD kidneys. Finally, we will discuss 
whether the implementation of utility-based allocation strategies for deceased donor 
kidneys is an appropriate way forward to provide a balance between utility and equity in 
the distribution of deceased donor kidneys. 
2. Live-donor kidney transplantation 
Since its introduction over 50 years ago, live-donor kidney transplantation is associated with 
better graft and patient outcomes compared with deceased donor kidney transplantation. 
The majority of live-related kidney transplantation is from siblings and parents, although 
spousal donation is becoming increasingly more common. There have been many live donor 
factors that have been identified which could affect transplant outcomes and this will be 
discussed in greater details in this chapter.  
2.1 Trends In live donor transplantation 
Live-donor renal transplantation has increased considerably over time, with some countries 
like the United States and Australia reporting an increase of at least 50% over the past 
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decade(Horvat, Shariff et al. 2009). Even in countries without a deceased donor renal 
transplant program such as the Middle East and Asia, live-donor renal transplantation 
continues to grow substantially(Ghods and Savaj 2006; Horvat, Shariff et al. 2009). It is 
currently estimated that live-donor renal transplantation accounts for over 40% of total renal 
transplant numbers worldwide. According to the Australia and New Zealand Dialysis and 
Transplant (ANZDATA) Registry report, the proportion of live-donor renal transplantation 
has increased from 31% in 1998 to 44% in 2008 (Figure 1)(Campbell, McDonald et al. 2009). 
Similar increases have been reported in other countries including Europe and the United 
States (De Meester 1998; Oosterlee and Rahmel 2008; Horvat, Shariff et al. 2009; US Organ 
Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 
2009; ERA-EDTA Registry 2010).  
Within the United States, Europe and Australia, the increased rates of live-donor renal 
transplantation are directly attributable to growth of live-unrelated donor (LURD) kidney 
transplants (Oosterlee and Rahmel 2008; Campbell, McDonald et al. 2009; US Organ 
Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 
2009; ERA-EDTA Registry 2010). In Australia, the proportion of LURD has increased 
substantially from 31% of overall live-donor transplants in 2000 to 50% in 2008. The majority 
of live-related donor (LRD) kidney transplants are from parental or sibling donors, whereas 
spousal donation accounts for the majority of LURD transplants. Furthermore, the adoption 
of laparoscopic donor nephrectomy techniques coupled with low rates of short- and long-
term complications of kidney donation has also contributed significantly to the expansion of 
live-donor transplantation (Bia, Ramos et al. 1995; Schweitzer, Wilson et al. 2000).  
Finally, there is greater acceptance of older live-donors over the past decade despite donor 
age having been shown to affect renal transplant outcomes.  In the United States, the 
proportion of older donors >50 years age has increased by almost 7% between 1999 and 
2008, with similar proportional increase in other countries (US Organ Procurement and 
Transplantation Network and Scientific Registry of Transplant Recipients 2009).  
 
 
 
 
 
Fig. 1. Living donor transplants as proportion of total transplants. 
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2.2 Outcome of live compared to deceased-donor kidney transplantation 
Live-donor transplantation is associated with superior graft and patient outcomes 
compared with deceased-donor transplantation (Table 1) (Terasaki, Cecka et al. 1995; 
Gjertson and Cecka 2000; Campbell, McDonald et al. 2009; US Organ Procurement and 
Transplantation Network and Scientific Registry of Transplant Recipients 2009).  In 
addition, the introduction of pre-emptive live-donor renal transplantation provides ESKD 
patients the option of avoiding dialysis (Mange, Joffe et al. 2001; Meier-Kriesche and 
Kaplan 2002; Liem and Weimar 2009). Finally, it has been established by several large 
single centre and registry studies that the superior outcomes of live-donor transplantation 
occur independently of human leukocyte antigen (HLA)-matching and donor or recipient 
characteristics (Terasaki, Cecka et al. 1995; Gjertson and Cecka 2000; Fuggle, Allen et al. 
2010).  
Large registry analyses from the United States, Europe and Australia have demonstrated a 
significant graft and/or patient survival advantage and possibly reduction in rejection risk 
in pre-emptive live-donor transplants compared to non-pre-emptive live-donor transplants, 
possibly related to avoidance of dialysis exposure (Donelly, Oman et al. 1995; Mange, Joffe 
et al. 2001; Milton, Russ et al. 2008). However, one study suggested that short duration of 
dialysis of <90 days prior to transplant had comparable graft survival to pre-emptive 
transplant recipients (Milton, Russ et al. 2008). Interestingly, unlike pre-emptive live-donor 
transplantation, pre-emptive deceased donor transplantation does not appear to be 
associated with improved graft or patient survival compared to non-pre-emptive deceased 
donor transplantation (Kessler, Ladriere et al. 2011).  
 
 
1 year graft / 
patient 
survival 
5 year graft / 
patient 
survival 
10 year graft / 
patient 
survival 
Australia 
Live 96.8% / 98.7% 87.5% / 94.1% 68.8% / 86.7% 
Deceased 91.6% / 96.4% 80.8% / 89.0% 58.6% / 72.6% 
United States 
Live 95.7% / 98.3% 80.4% / 90.2% 57.0% / 76.5% 
Deceased 90.5% / 95.2% 67.3% / 80.7% 41.0% / 60.6% 
Table 1. Unadjusted 1, 5 and 10-year graft and patient survival rates following primary 
living and deceased donor transplantation in Australia & United States in 2008 (Campbell, 
McDonald et al. 2009; US Organ Procurement and Transplantation Network and Scientific 
Registry of Transplant Recipients 2009). 
2.3 Effect of donor characteristics on live-donor kidney transplant outcomes  
2.3.1 Donor gender 
A disproportionately greater number of female donors have been observed in live-donor 
programs in most countries, including the United States and Australia(Kayler, Meier-
Kriesche et al. 2002; Campbell, McDonald et al. 2009). In Australia, female donors 
accounted for 53% and 62% of overall LRD and LURD donors respectively, the latter 
likely to reflect the growth in spousal donation (Campbell, McDonald et al. 2009). The 
reason for the greater proportion of female donors remains unclear although differences 
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in medical (higher rates of cardiovascular disease in men) and psychosocial (financial 
issues and differing perception towards donation between genders) factors may be 
contributing (Bloembergen, Port et al. 1996; Schaubel, Stewart et al. 2000; Zimmerman, 
Donnelly et al. 2000).  
In deceased donor kidney transplants, female donors have been shown to be associated with 
higher rates of rejection, poorer post-transplant graft function and possibly reduced graft 
and patient survival (Vereerstraeten, Wissing et al. 1999; Zeier, Dohler et al. 2002). In live-
donor kidney transplantation, large single centre studies have suggested that female donors 
are associated with a greater risk of rejection and poorer post-transplant graft function 
(Oien, Reisaeter et al. 2005; Oien, Reisaeter et al. 2007), but this association has not been 
observed in large registry analyses (Kayler, Rasmussen et al. 2003; Lim, Chang et al. 2007). 
The failure to account for differences in donor-recipient body mass in these studies may in 
part explain the conflicting results between studies. It is plausible that the inverse 
association between female donors and post-transplant graft function may be attributed to 
‘inadequate’ nephron mass from smaller female donors into larger male recipients with 
subsequent hyperfiltration injury and decline in renal function (Brenner, Cohen et al. 1992; 
Brenner, Lawler et al. 1996). Supporting this explanation, Poggio et al demonstrated that 
donors with larger kidney volume (typically donors with larger body sizes and male 
donors), as determined by 3D helical computed tomography scanning, were associated with 
lower rejection risk and improved post-transplant radionuclide glomerular filtration rate 
(GFR) (Poggio, Hila et al. 2006). However, selective transplantation of donor and recipient 
pairs based on size-matching remains debatable. 
2.3.2 Donor-recipient relationship 
A number of large single centre studies and registry analyses including United Network of 
Organ Sharing (UNOS) and ANZDATA have demonstrated similar graft and patient 
outcomes between LRD and LURD transplants, even though LURD were more likely to be 
older donors and often have poorer HLA-matching (Figure 8)(Terasaki, Cecka et al. 1995; 
Gjertson and Cecka 2000; Humar, Durand et al. 2000; Lim, Chang et al. 2007). Early studies 
have indicated that husband-to-wife (Terasaki, Cecka et al. 1997; Rosenberg, Jones et al. 
2004) and child-to-mother live-donor transplants were associated with an increased risk of 
rejection and graft failure (Cecka 1995; Mahanty, Cherikh et al. 2001), possibly related to 
prior exposure to donor HLA antigens during pregnancy (Miles, Schaubel et al. 2008; 
Fuggle, Allen et al. 2010). In a recent ANZDATA analysis of 1989 primary live-donor renal 
transplants between 1995 and 2004, Lim et al reported that the risk of graft and patient 
survival was similar between LRD and LURD transplants. In this study, parental donors 
were associated with an increased risk of acute rejection at 6 months (odds ratio [OR] 1.69, 
95% confidence interval [CI] 1.13-2.53) and lower GFR at 1 and 3 years post-transplant, but 
this did not translate to inferior graft or patient survival (Lim, Chang et al. 2007). In contrast, 
husband-to-wife and child-to-mother transplants were not associated with poorer graft 
outcomes in this study. Analysis of the UNOS database suggested that in recipients with 
genetic-predisposed ESKD such as focal segmental glomerulosclerosis (FSGS), type I 
diabetes and polycystic kidney disease (PKD), LRD kidney transplants may be associated 
with poorer graft outcomes compared with LURD transplants but this association remains 
debatable (Futagawa, Waki et al. 2005).  
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2.3.3 Expanded-criteria live donors 
As with deceased donors, certain live donor characteristics have been identified that may 
have a significant impact on renal allograft outcomes. The identification of these donor 
characteristics in the assessment of potential live donor-recipient pairing may help in the 
selection of the most appropriate live donor to achieve the best graft outcomes. A large 
retrospective chart review of 264 live donor-recipient pairs transplanted between 1997 and 
2003 at Cleveland clinic demonstrated that older donor age 45 years (compared with <45 
years), donor radionuclide GFR 110mL/min (compared with >110mL/min), donor systolic 
blood pressure 120mmHg (compared with <120mmHg) and donor cholesterol 200mg/dL 
(compared with <200mg/dL) were associated with a greater risk of acute rejection, delayed 
graft function (DGF), poorer post-transplant graft function and/or graft loss at 2 and 3 years 
post-transplantation in the adjusted model. What was interesting about this study were the 
additive negative effects of increasing number of donor factors on graft function. In this 
study, there was no association between donor uric acid, fasting glucose, gender or race and 
graft outcomes (Issa, Stephany et al. 2007). Other studies have demonstrated a similar strong 
independent relationship between live donor GFR and post-transplant graft function 
(Poggio, Hila et al. 2006).  
The recent meta-analyses by Iordanous Y et al of living expanded criteria kidney donors 
demonstrated that older live donors were associated with poorer composite outcomes of 
graft and patient survival compared to younger donors (meta-analysis of 12 studies, 72% vs. 
80%, unadjusted relative risk [RR] of survival 0.89, 95% CI 0.83-0.95). However, the 
association between donor age and survival appeared to diminished over time (1980 - RR 
0.79, 95% CI 0.65-0.96 compared to 1990 - RR 0.91, 95% CI 0.85-0.99), possibly related to the 
use of more potent immunosuppression (Iordanous, Seymour et al. 2009). The relationship 
between donor hypertension or lipid level and graft outcomes in this study remains unclear. 
Studies examining the association between donor obesity and donor urinary abnormalities 
(i.e. presence of proteinuria and/or haematuria pre-donation) are lacking. When examining 
live donor-recipient age difference, Ferrari P et al demonstrated that live donor-recipient 
pairs with 30 years age difference had similar graft and patient outcomes as those with 
lesser donor-recipient age difference suggesting large discrepancy in donor-recipient age 
difference should not discourage the decision for transplantation (Ferrari, Lim et al. 2011).  
It is important to acknowledge that these are retrospective studies and therefore do not 
clearly establish causality between live donor factors and renal graft outcomes.  
Nevertheless, identifying unfavorable live donor characteristics could complement the 
assessments of recipients in stratifying their post-transplant risk of graft dysfunction or 
failure. 
3. ABO-incompatible and desensitization programs 
The complexity of live- and deceased donor transplantation has evolved over the years such 
that many transplanting centres are performing ABO-incompatible transplants and 
desensitizing highly allo-sensitized transplant candidates to improve their transplant 
potential. Other innovative programs that have been established to enhance live-donor 
transplantation include the paired kidney exchange program (as a strategy to overcome 
incompatible transplants) and tumour-resected kidney transplant program whereby 
patients with small renal tumours are considered for kidney donation following radical 
nephrectomy and resection of renal tumour. 
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3.1 ABO-incompatible live-donor transplants 
Alexandre et al first described transplantation across the blood group barrier in 1987, but 
there has since been a broad expansion of this program worldwide (Alexandre G 1987). 
With the greater availability of more potent immunosuppression coupled with the 
capability to measure isohemagglutinin antibodies, the outcomes of ABO-incompatible live-
donor kidney transplantation are comparable to compatible live-donor kidney 
transplantation (Crew and Ratner 2010). However, there continues to be an early significant 
risk of antibody-mediated rejection (AMR). The concept of blood group incompatible 
transplantation involves the removal of isohemagglutinin antibodies (i.e. antibodies formed 
against blood group antigen A and/or B) to low levels using immunoabsorption technique 
(ABO antibody-specific) or plasmapheresis (not ABO antibody-specific) thereby avoiding 
hyperacute rejection following transplantation. Although splenectomy was once considered 
standard practice pre-blood group incompatible transplantation to prevent early AMR, the 
introduction of anti-CD20 antibody rituximab has largely eliminated the need for 
splenectomy achieving equivalent outcomes. However, the need for pre-transplant 
rituximab remains debatable (Tanabe, Ischida et al. 2009).  
Tanabe et al recently reported on the outcome of 800 ABO-incompatible kidney transplants in 
Japan performed since 1989. The reported 5-year graft and patient survival in this cohort 
was 79% and 90% respectively (Tanabe K 2007). Acute AMR occurred in up to 30% of 
transplant recipients resulting in early graft loss in 10% of recipients with refractory AMR 
(Crew R 2010). Although acute AMR may be treated successfully with further 
immunoabsorption or plasmapheresis, recipients who develop AMR have poorer graft 
survival (AMR and no AMR - graft survival of 84% and 100% at 3 years and 49% and 95% at 
8 years) and a greater risk of developing transplant glomerulopathy, especially in recipients 
with concurrent pre-transplant donor specific antibodies (DSA) (Einecke, Sis et al. 2009; 
Toki, Ishida et al. 2009). Acute AMR is less common after 3 months post-transplant, 
presumably related to the development of accommodation, a phenomenon of persistent 
anti-donor antibody in the absence of allograft injury (Dehoux and Gianello 2009).  
3.2 ABO-incompatible deceased donor transplants 
In 1991, an Organ Procurement Transplant Network (OPTN)/UNOS variance has approved 
a voluntary national allocation of blood group A2 and A2B deceased donor kidneys into 
blood group B and O transplant candidates to improve their transplant potential, although 
this allocation practice had already been adopted into clinical practice by the Midwest 
Transplant Network since 1986 (Nelson, Shield et al. 2002). As a result of this practice, 31% 
more blood group B transplant candidates with low anti-A IgG titres received a transplant 
achieving comparable graft survival as those who had received blood group B kidneys 
using conventional immunosuppression (10 year graft survival was 72% and 69% 
respectively) (Bryan, Nelson et al. 2004; Bryan, Winklhofer et al. 2005). Recent analysis of the 
United States Renal Data System (USRDS) database between 1995 and 2006 demonstrated 
that blood group O and B recipients (n=238) who had received blood group A2 kidneys had 
significantly shorter waiting-time compared to blood group compatible transplants 
(n=149,880). Graft loss and patient survival were similar in blood group A2 to B or O 
recipients and blood group compatible recipients (Hurst, Sajjad et al. 2010). These 
favourable reports suggest that this strategy should be considered in allocation programs to 
enhance the transplant potential of appropriate blood group B and O transplant candidates 
with low anti-A titres.  
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3.3 Desensitization of highly-sensitized patients for live-donor transplantation 
There is an increasing number of transplant candidates who are allo-sensitized to HLA as a 
result of previous exposure to HLA antigens, typically following blood transfusions, prior 
transplantation and pregnancy. The presence of high levels of class I and/or II DSA (i.e. 
anti-HLA antibodies with reactivity against the potential donor leading to positive 
complement-dependent cytotoxicity [CDC] cross-match) is associated with poorer graft 
outcomes, including the development of acute and chronic AMR, transplant 
glomerulopathy and late graft loss (Eng, Bennett et al. 2008; Gloor, Winters et al. 2010; Eng, 
Bennett et al. 2011; Mujtaba, Goggins et al. 2011). A study by LeFaucheur et al demonstrated 
that the presence of DSA significantly reduces graft survival rates compared to recipients 
without DSA (1 year graft survival – 81% and 94% respectively and 8 years graft survival 
47% and 78% respectively) (Lefaucheur, Suberbielle-Boissel et al. 2008) (Table 2). In addition, 
recent study by Mujtaba M et al demonstrated that the 3-year graft survival in highly-
sensitized patients with lower total DSA (i.e. total mean fluorescent intensity [MFI] of <9500) 
was 100% compared to 76% in those with higher total DSA (i.e. total MFI >9500; p = 0.022) 
(Mujtaba, Goggins et al. 2011).  
Studies reporting the utilization of desensitization technique to allow transplantation in 
highly-sensitized transplant candidates have focused predominantly on live-donor 
transplantation, which allows early planning and implementation of treatment at a suitable 
time. With the greater understanding of HLA antigens and anti-HLA antibodies, innovative 
techniques have been established to allow live-door transplantation across a ‘positive CDC 
cross-match’ barrier. Combinations of rituximab, plasmapheresis and/or intravenous 
immunoglobulin (IVIg) have been used successfully to desensitize highly allo-sensitized 
transplant candidates, therefore allowing live-donor transplantation to occur safely (Jordan, 
Vo et al. 2003; Gloor and Stegall 2010). The typical desensitization regimens involve either a 
single high dose of IVIg or combination plasmapheresis with low dose IVIg, although the 
latter may be more effective in achieving a negative CDC cross-match (Gloor, DeGoey et al. 
2003; Stegall, Gloor et al. 2006). The addition of rituximab remains debatable and 
unsubstantiated and splenectomy has largely been eliminated from most desensitization 
protocols (Locke, Zachary et al. 2007). Current literature indicates that transplantation could 
safely proceed if DSA intensity is lowered sufficiently to render a negative CDC cross-match 
and/or an IgG titre of 16 by isohemagglutination. Following successful transplantation, 
ongoing monitoring of DSA and early recognition of AMR is crucial to avoid early graft loss. 
On re-exposure to donor antigens against which the recipient is sensitized, memory B 
lymphocytes in their spleen, bone marrow and lymph nodes undergo an amnestic reaction 
leading to the development of antibody-producing cells, which can produce high levels of 
DSA within days or weeks suggesting positive cross-match kidney transplantation requires 
both pre- and post-transplantation interventions to continually suppress DSA levels. Despite 
advances in desensitization techniques, AMR and transplant glomerulopathy occur in over 
30% and 45% respectively in live donor positive cross-match kidney transplantations (Gloor 
J 2010).  
3.4 Desensitization of highly-sensitized patients on deceased donor wait-list 
Desensitization of deceased donor transplant wait-list candidates with multiple anti-HLA 
antibodies to enhance their transplant potential remains debatable due to the uncertain 
availability of deceased donor kidneys and these patients may remain on the deceased donor 
transplant wait-list indefinitely (Table 2). Vo et al reported the successful transplantation of 6 
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highly sensitized patients who received deceased donor kidneys following desensitization 
with IVIg (2g/kg on days 0 and 30) and rituximab (1g on days 7 and 22) over a 4-week period. 
These patients were on the deceased donor wait-list for 14489 months (range 60-324 months), 
but had waited only an additional 56 months for a transplant. These patients achieved 
excellent graft and patient outcomes despite having a greater risk of acute rejection (Vo, 
Lukovsky et al. 2008). The same group reported an additional 45 successful deceased donor 
transplants in highly sensitized patients using a similar but modified desensitization approach 
using one instead of two doses of rituximab. In this cohort, desensitized patients waited for an 
additional 4.2±4.5 months before receiving a deceased donor graft. Overall graft failure and 
death at 2 years were 80% and 91% respectively, but almost 30% of graft loss was directly 
attributed to AMR (Vo, Peng et al. 2010).  
 
 
Number of 
patients 
AMR 
incidence (%) 
1-year DCGS 
(%) 
2-year DCGS 
(%) 
Lefaucheur et al 
(2008) 
43 35 89 89 
Thielke et al 
(2009) 
51 32 93 81 
Magee et al 
(2008) 
28 39 92 89 
Gloor et al 
(2010) 
119 41 89 89 
Haririan et al 
(2009) 
41 12 90 85 
Vo et al (2008) 16 30 94 Not reported 
Vo et al (2010)# 76 29 87 84 
Table 2. Incidence of antibody mediated rejection (AMR) and death-censored graft survival 
(DCGS) following positive-crossmatch kidney transplantation. #Stratified by donor type – 
DCGS at 1 and 2 years for live donor (LD) 90% and 90%; for deceased donor (DD) 82% and 
80%. 
4. Innovative live-donor programs 
4.1 Paired kidney exchange 
Blood group or cross-match incompatibility between a potential donor-recipient pair is often 
a major barrier for kidney transplantation. Paired kidney exchange (PKE), which was first 
described in 1986 (Rapaport F 1986), circumvents the incompatibility by allowing a live-
donor to direct the donated kidney to a different but compatible recipient, with the intent 
that another donor will donate to the first donor’s designated recipient (Delmonico 2004). 
Most PKE programs involves the use of computer-generated algorithms to create potential 
donor-recipient pairings using virtual databases containing patient characteristics along 
with blood group types and degree of sensitization (de Klerk, Keizer et al. 2005).  There are 
several alternatives to the conventional 2-way or 3-way kidney paired donation types, such 
that an altruistic donor could create a domino paired donation (i.e. kidneys from altruistic 
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donor set off a chain of simultaneous transplants terminating in a donation to a candidate 
on the deceased donor wait-list) (Gentry, Montgomery et al. 2011). Although overcoming 
incompatibility remains the primary focus of PKE, donor and recipients pairs may 
participate in the exchange in the hope of finding a better HLA-matched kidney or younger 
kidney amongst other reasons. Match rates for incompatible pairs can be as high as 50% (de 
Klerk M 2006) and as a result can increase transplant activity even in small populations by 
almost 10% (Ferrari P 2009). Successful PKE programs have been established in the 
Netherlands, South Korea, United Kingdom, United States and more recently Australia.  
4.2 Tumour-resected kidney transplant program 
Transplantation of donor kidneys following ex-vivo resection of small kidney tumours is a 
novel source of donor kidneys that was first described in 1995 (Penn I 1995). Although these 
kidneys are clearly outside the standard criteria for donor kidneys coupled with the small 
but potential transmission of donor-derived malignancy into recipients, the success of such 
program in many countries is encouraging.  
The largest reported case series of utilizing donor kidneys with small renal cancers comes 
from Australia. In this single-centre program, 43 patients were transplanted with kidneys 
removed from patients with <3cm incidentally detected renal cell cancer, majority of which 
were patients undergoing radical nephrectomy for presumed renal cell cancer. In this 
program, a vigorous informed consent was undertaken and only older transplant 
candidates >60 years of age or those with significant comorbidities were eligible to receive 
these kidneys (Nicol D 2008). In this program, patient survival at 1 and 5 years of recipients 
of tumour-resected kidney transplants was 92% and 88% respectively, compared to 98% and 
74% patient survival for patients on the deceased donor wait-list (n=153) and 99% and 97% 
patient survival for recipients of LURD renal transplants (n=120; log rank score 10.4, P = 
0.005) (Brook, Gibbons et al. 2010). There was one tumour recurrence occurring at 9 years 
post-transplantation, but it was unclear whether this was donor-derived. An additional 22 
similar successful cases from United States and Japan were reported with no documented 
tumour recurrence (Buell J 2005; Mannami, Mannami et al. 2008).  
5. Deceased donor kidney transplantation 
There continues to be an enormous disparity between the availability of deceased-donor 
kidneys and potential recipients. This problem is further exacerbated by a greater 
acceptance of older ESKD patients for renal replacement therapy. In Australia, acceptance of 
ESKD patients aged 70-74 years for renal replacement therapy has increased from 390 per 
million population (pmp) in 2004, to 469 pmp in 2008 (McDonald, Excell et al. 2009). 
Furthermore, the proportion of potential transplant candidates aged >65 years on the 
deceased donor wait-list has increased by 21% between 2005 and 2008 (Chadban, McDonald 
et al. 2006; Campbell, McDonald et al. 2009). The Scientific Registry of Transplant Patients 
(SRTR) has recorded a similar increase of prevalent potential recipients aged ≥70 years on 
the deceased donor wait-list, rising from 114 in 1990 to 2544 in 2004 (Rao, Merion et al. 
2007). There has been little increase in deceased donor rates worldwide. In Australia, 
deceased donor rates have remained low at 11 donors pmp in 2009 (10 pmp in 2005), 
compared to 34 pmp in Spain, 24 pmp in United States and 17 pmp in the United Kingdom 
(Excell, Hee et al. 2010; Fabre, Murphy et al. 2010). However, there has been an increase in 
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acceptance of older donor kidneys in Australia, with the number of deceased donors aged 
≥55 years increasing 1.8-fold between 2001-03 to 2007-09 (Excell, Hee et al. 2010). Kidneys 
from older donors are associated with poorer graft outcomes including late graft loss, 
chronic allograft nephropathy and higher risk of cardiovascular mortality (Meier-Kriesche, 
Cibrik et al. 2002; Oppenheimer, Aljama et al. 2004); this is partially offset by the reduction 
in mortality associated with reduced wait-list time. In addition, female-to-male donation, 
major donor kidney weight/recipient weight inadequacy, cerebrovascular accidents (CVA) 
as the cause of donor death and the presence of donor comorbidities such as diabetes have 
an adverse impact on graft and/or patient survival (Feldman, Fazio et al. 1996; Giral, 
Nguyen et al. 2005; Ahmad, Cole et al. 2009; Shaheen, Shaheen et al. 2010). However, 
utilization of kidneys from deceased donors who had developed acute renal failure prior to 
organ procurement does not appear to have an unfavorable effect on graft outcome 
(Deroure, Kamar et al. 2010). A continuous kidney donor risk index has been developed 
using registry data to quantify expected graft survival for any given set of donor 
characteristics relative to a healthy 40-year old donor and may be useful as a decision-
making tool at the time of the deceased donor kidney offer (Rao, Schaubel et al. 2009). 
However, the significance of such index in the different transplant eras or population 
groups remains unclear. In the remaining chapter, we will focus primarily on the use and 
outcomes of ECD and DCD donor kidneys, which have become important source of 
deceased donor kidneys over the last decade.  
5.1 Expanded-criteria donor (ECD) kidneys (Table 3) 
With the ongoing shortage of deceased donor kidneys coupled with the continued growth 
of potential transplant candidates, there has been an increase utilization of ECD kidneys. 
Compared with non-ECD kidneys, ECD kidneys are associated with poorer graft outcomes. 
Between 2005 and 2009 in Australia, there has been a 1.3-fold increase in the number of ECD 
kidneys (Excell, Hee et al. 2006; Excell, Hee et al. 2010) 
In 2002, OPTN/UNOS Board of Directors established a definition of ECD kidneys, which 
was based on a retrospective review of 29,068 recipients from SRTR database (Port FK 
2002). The term ECD kidneys was assigned based on a 70% greater risk of developing 
graft failure when compared to younger donor kidneys (aged between 10 and 39 years) 
and defined as any donor aged ≥60 years, or any donor aged 50-59 years, with two of the 
following three donor criteria: CVA death, terminal creatinine >133mol/L, or 
hypertension (Metzger, Delmonico et al. 2003). Although the concept of ECD focuses 
primarily on advanced donor age, other risk factors such as CVA, hypertension, diabetes 
and high serum creatinine were also taken into account (Cosio, Qiu et al. 1996; Ojo, 
Leichtman et al. 2000). Multiple studies have demonstrated that recipients of ECD kidneys 
have better survival compared to potential recipients on the waiting-list but long-term 
outcomes associated with ECD grafts remains unclear (Wolfe, Ashby et al. 1999; Ojo, 
Hanson et al. 2001).  
Further modification of the definition of ECD kidneys has been proposed in an attempt to 
further improve the stratification and identification of donor kidneys with increased risk of 
early graft dysfunction or graft loss. In 2001, Nyberg et al devised the Deceased Donor Score 
(DDS), which incorporated several donor-derived factors that have been shown to 
independently affect graft outcomes (Nyberg SL 2001; Nyberg SL 2003). However, this score 
has not been adopted widely for clinical application.   
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In a retrospective study of 2845 French transplant recipients aged 60 years, ECD kidneys 
were associated with poorer graft survival compared to non-ECD kidneys (Savoye, 
Tamarelle et al. 2007). The difference in graft survival was 6.2% at 12 months and 14.2% at 5 
years (adjusted relative risk [RR] of graft failure associated with ECD kidneys compared to 
non-ECD kidneys was 1.98, p<0.01). Nonetheless, survival of ECD recipients was superior to 
potential recipients remaining on the waiting list (adjusted RR of potential recipients on 
waiting-list compared to recipients of ECD and non-ECD kidneys were 2.32 and 3.78 
respectively, p<0.0001). Similarly, analysis of the SRTR between 1990 and 2005 
demonstrated that recipients aged ≥70 years receiving ECD or non-ECD deceased donor 
kidneys had a 56% lower mortality risk compared to wait-listed dialysis patients aged ≥70 
years (RR 0.59; 95%CI 0.53, 0.65; p<0.0001), and this benefit persisted in elderly patients with 
diabetes and hypertension (Rao, Merion et al. 2007). As the unadjusted 1-year graft and 
death-censored graft survival (DCGS) of elderly transplant recipients were 81% and 90% 
respectively; and were 67% and 85% respectively at 3years, this suggested that a 
considerable proportion of these recipients die with functioning grafts.  
A retrospective analysis of ANZDATA of 4466 deceased donor transplants between 1991 
and 2005 reported poorer outcomes in recipients of ECD kidneys, compared to non-ECD 
kidneys (Collins, Chang et al. 2009). Compared to non-ECD kidneys, ECD kidneys were 
associated with poorer graft function and a greater risk of DGF, acute rejection and death-
censored graft failure (DCGF).  
The observed reduction in graft survival in recipients of ECD kidneys is likely related to an 
increase in glomerulosclerosis with the associated reduction in functional nephron mass, 
which has been shown to correlate with an increased risk of DGF, graft loss and poorer graft 
function (Gaber, Moore et al. 1995). On average, the adjusted graft survival of ECD kidneys 
is 8% lower at 1 year and up to 20% lower at 3-5 years compared to non-ECD kidneys (Ojo 
AO 2001).  
Although ECD kidneys are associated with poorer outcomes compared to non-ECD 
kidneys, the contribution of donor age, especially the upper acceptable age limit on graft 
outcomes amongst ECD grafts remains unclear. In a retrospective analysis of the 
UNOS/OPTN database, the impact of donor age on 9580 ECD kidneys were examined 
(Chavalitdhamrong, Gill et al. 2008). There was no association between donor age and acute 
rejection, although ECD kidneys from donors aged 70 years had poorer function at 12 
months compared to grafts from younger ECD donors. In an adjusted model, ECD kidneys 
from donors aged 70 years were associated with an increased risk of graft failure and 
patient death compared to ECD kidneys from donors aged 50-69 years (hazard ratio [HR] 
1.37 and 1.37 respectively, p<0.01). When stratified by recipient age, ECD kidneys from 
donors aged 70 years (compared to ECD 50-69 years) were associated with an increased 
risk of DCGF for recipients aged 41-60 years (HR 1.48, 95%CI 1.06, 2.06; p=0.02) but not for 
older recipients aged >60 years (HR 1.12, 95%CI 0.86, 1.46; p=0.40), suggesting that older 
ECD kidneys may have a smaller unfavourable impact in older recipients. In contrast, an 
Italian study demonstrated that 3-year graft and patient survival was similar in recipients 
receiving ECD kidneys from donors >75 years and <75 years (Collini, Kalmar et al. 2009). 
This inconsistent finding may be explained by the greater use of double kidneys (from 
donors >75 years) in the Italian study.  
As ECD kidneys are more susceptible to peri-transplant insults, strategies to reduce cold 
ischemic time, improve donor kidney preservation (Burdick JF) and preventing or reducing 
reperfusion injury using agents such as superoxide dismutase (Land W) or platelet-
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activating factor receptor antagonists (Grino JM) may be beneficial. However, these 
strategies have not translated to improvement in renal graft outcomes. Initial avoidance of 
calcineurin-inhibitors (CNI) in early post-transplant period has been suggested to reduce the 
risk of DGF in recipients of ECD kidneys but this approach has not been adopted widely.   
Although there is a lack of consensus amongst transplant physicians and surgeons 
regarding the allocation of ECD kidneys, most would advocate selective utilization of these 
kidneys for older recipients (particularly avoiding recipients <40 years) (Merion, Ashby et 
al. 2005; Schold and Meier-Kriesche 2006), for recipients with extended wait-time (Carter, 
Chan et al. 2005; Cecka, Cohen et al. 2006) or to consider dual graft transplantation into a 
single recipient to avoid unnecessary discard of older donor kidneys (Waiser, Schreiber et al. 
2000; Tan, Alfrey et al. 2004).  
 
 
Donor/recipient 
groups 
Graft outcome Patient outcome 
Collins M et al 2009 
ANZDATA (n=4466) 
 
Non-ECD <50y 
Non-ECD 50-59y 
ECD 50-59y 
ECD 60y 
1 / 5y DCGS* 
94% / 88% 
91% / 84% 
87% / 81% 
87% / 71% 
1 / 5y patient survival* 
97% / 92% 
97% / 90% 
97% / 89% 
96% / 87% 
Collini A et al 2009 
Single centre (n=192) 
 
ECD >75y 
ECD <75y 
1 / 3y graft survival 
73% / 64% 
82% / 71% 
10y patient survival 
81% / 81% 
92% / 90% 
Savoye E et al 2009 
Single centre (n=2845) 
 
Expanded criteria 0^ 
Expanded criteria 1^ 
Expanded criteria 2^ 
Expanded criteria 3^ 
1 / 5y graft survival#
93% / 83% 
87% / 74% 
87% / 65% 
83% / 55% 
1 / 5y patient survival 
ECD – 97% / 67% 
Non-ECD – 98% / 
91% 
Chavalitdhamrong D et 
al 2008; OPTN/UNOS 
database (n=9580) 
 
ECD 50-69y 
ECD 70y 
3 / 5y graft survival* 
69% / 55% 
62% / 44% 
3 / 5y patient survival* 
82% / 71% 
75% / 58% 
Table 3. Effect of expanded criteria donor on renal transplant outcomes. *p<0.05; #analysis 
in patients aged 60 years, ^expanded criteria risk factors including donor aged >60 years, 
donor hypertension, donor diabetes, donor death from cerebrovascular accident. 
Abbreviation: ANZDATA – Australia and New Zealand Dialysis and Transplant Registry, 
ECD – expanded criteria donor, OPTN – Organ Procurement Transplant Network, UNOS – 
United Network of Organ Sharing, y – year(s). Adapted from Lim et al (Nephrol Dial 
Transplant 2010). 
5.2 Donation after cardiac death donor kidneys 
Over the last decade, the number of brain-death donors has steadily declined, in part 
attributed to changes in neurosurgical practice (Jüttler, Schwab et al. 2007). However, the 
use of DCD donor kidneys has increased substantially. In Australia, the number of DCD 
donors has increased from 1 to 42 between 2000 and 2009 (Excell, Hee et al. 2010), whereas 
in the United Kingdom, the proportion of DCD of all deceased donors has increased by 29% 
between 2000 and 2009 (Transplant 2010). The prolonged warm ischaemic period that 
invariably accompanies DCD kidney transplants is likely to explain the greater incidence of 
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DGF (Locke, Segev et al. 2007). As a result, DCD kidneys are more likely to be allocated 
locally to minimize cold ischaemic time. Recent analysis of the UK transplant registry 
demonstrated that compared with brain-death donor kidney transplants, recipients of 
controlled DCD donor kidneys of Maastricht category 3 (defined as donors awaiting cardiac 
arrest following withdrawal of life-sustaining treatment in intensive care unit (Kootstra, 
Daemen et al. 1995)) was associated with a significantly greater risk of DGF but lower risk of 
acute rejection up to 3 months post-transplant (Figure 2). For primary but not repeat renal 
allograft recipients of DCD kidneys, overall 5-year graft survival was comparable to 
primary and repeat renal allograft recipients of brain-death donor kidneys in unadjusted 
and adjusted models. Repeat renal allograft recipients of DCD kidneys have a greater risk of 
primary non-function compared to primary renal allograft recipients of DCD kidneys. 
Increasing donor and recipient age, as well as prolonged cold ischaemic time but not the 
presence of DGF or HLA-matching were associated with poorer graft outcomes in primary 
renal allograft recipients of DCD kidneys (Summers, Johnson et al. 2010). With comparable 
transplant outcomes between brain-death and controlled DCD donor kidneys, DCD kidneys 
are considered an acceptable source of donor kidneys although particular attention in 
reducing cold ischaemic time and avoidance of large donor-recipient age differences and 
avoidance of allocating DCD kidneys to repeat renal allograft recipients may be appropriate.   
 
 
Fig. 2. Kaplan-Meier survival estimates comparing brain-death and cardiac-death donor   
grafts, stratified by primary and repeat grafts (adapted from Summers et al 2010). 
5.3 Utility-based allocation strategies to maximise overall functioning graft years 
Allocating younger donor kidneys to older potential recipients has raised concerns amongst 
many transplant physicians and surgeons, as many older recipients will die with 
functioning grafts. If these younger kidneys were re-allocated from older to younger 
recipients, a proportion may have continued to function for a substantial period in younger 
recipients. As older recipients have reduced life expectancies, adopting an allocation 
strategy that better matches the life expectancy of the donor kidney with that of the recipient 
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may be more appropriate (Meier-Kriesche, Schold et al. 2005). Allocation strategies that have 
been examined included the concept of donor-recipient age-matching and the creation of a 
kidney allocation score (KAS) to improve the utility of deceased donor kidneys. These 
strategies will be discussed in this chapter.  
5.3.1 Age-matching 
Allocation of deceased donor kidneys according to donor-recipient age-matching avoids the 
allocation of younger donor kidneys to older recipients and older donor kidneys to younger 
recipients according to a single donor and recipient age cut-off value. The Eurotransplant 
Seniors Program (ESP) is an example of an age-matching allocation model that has been 
successfully implemented in the allocation of deceased donor kidneys.  
5.3.1.1 Eurotransplant seniors program  
The foundation of ESP, which was established in 1999, was to preferentially allocate older 
donor kidneys 65 years to ABO-compatible, unsensitized older recipients 65 years 
receiving a primary graft (Cecka, Cohen et al. 2006). The ESP was designed to match the 
functional potential of donor kidneys ≥65 years to the functional requirements of older 
recipients aged ≥65 years. Although a degree of age-matching already occurred prior to the 
development of ESP such that the very young donor kidneys were seldom allocated to older 
recipients, this may be explained by younger healthier potential recipients near the top of 
the list declining a suboptimal donor graft, and therefore retain their place on the waiting 
list until a younger donor kidney becomes available. Similar practice also occurs in countries 
such as the United States and Australia where age-matching is not part of the standard 
allocation process (Segev 2009; Lim, Chang et al. 2010).  
In ESP, donor kidneys were distributed locally to reduce cold ischaemic time, in an attempt 
to reduce the risk of DGF. Consequently, this program has not only resulted in an 
improvement in transplant access in older recipients by reducing wait-list times, younger 
recipients had also benefited from this program with improved access to younger donor 
kidneys (Smits, Persijn et al. 2002). Compared to ‘old-to-any’ (i.e. recipients of any age 
receiving a donor kidney ≥65 years) and ‘any-to-old’ (i.e. recipients aged between 60-64 
years receiving donor kidneys of any age) transplants (allocated via Eurotransplant Kidney 
Allocation System [ETKAS]), recipients of ESP had significantly lower risk of DGF; 
presumably related to the reduction in cold ischaemic time. However, ESP recipients had a 
greater risk of acute rejection, presumably related to a greater degree of HLA-mismatch(es), 
which was ignored in the allocation of ESP kidneys. One and 5-year DCGS in ESP recipients 
were similar to ‘old-to-any’ recipients (1 year – 83% and 81% respectively; 5 years – 67% for 
both groups) but were inferior compared to ‘any-to-old’ recipients (1 year 90% and 5 years 
81%) (Table 4). When stratified by donor age, the 1 and 5-year graft survival in the ESP 
group was 75% and 47% compared to 74% and 53% for ‘any-to-old’ recipients with older 
donors aged ≥60 years (p=0.38) and 85% and 67% for ‘any-to-old’ recipients with younger 
donors aged <60 years (p<0.001) suggesting older recipients receiving older donor kidneys 
allocated through the ETKAS system had similar outcome as ESP recipients. Although the 
risk of DGF was reduced in ESP recipients, this remained an important predictor of graft 
outcomes indicating that DGF may have a greater adverse impact on graft outcome in older 
recipients receiving older donor kidneys. It is conceivable that strategies to reduce the risk of 
DGF in ESP recipients (e.g. attempts to further reduce cold ischaemia) may lead to an 
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improvement in graft and patient outcomes. An important and often overlooked finding in 
this study is that younger recipients of older donor kidneys have poorer survival, similar to 
that of the ‘any-to-old’ recipients allocated through the ETKAS system (Table 4).  
Eurotransplant Senior DR-compatible Program is a new future initiative of the ESP to 
preferentially allocate kidneys to recipients with 0 HLA-DR mismatches and therefore 
potentially reducing the risk of rejection (de Fijter 2009). The outcome of this approach will 
be prospectively evaluated in the coming years. 
5.3.1.2 Simulated age-matching allocation of deceased donor kidneys  
In Australia, utilization of older donors has steadily increased, with donors aged ≥55 years 
increasing from 134 to 241 between 2001-03 and 2007-09 (i.e. an increase of 16% of overall 
donors) (Excell, Hee et al. 2010). A recent ANZDATA registry study of 4616 renal transplant 
recipients has demonstrated that the adoption an age-matching allocation model would lead 
to substantial improvement in the number of functioning graft years and associated cost 
savings (Lim, Chang et al. 2010). In this study, recipients ≥55 years had more than a 2.5-fold 
increased risk of death with functioning graft compared to recipients <55 years (HR 2.84, 
95%CI 1.97, 4.10 for 0-1 year; HR 2.78, 95%CI 2.19, 3.53 for 1-8 years and HR 4.44, 95%CI 
3.10, 6.35 for >8 years; all p-values <0.01). However, the risk of early (<1 year) and late (>8 
years) DCGF was similar in younger and older recipients. Compared with younger donor 
grafts, older donor grafts ≥60 years were associated with a significant increased risk of 
DCGF, death with functioning graft and poorer post-transplant graft function. The 
application of an age-matching allocation model to this cohort would result in an additional 
262 mean functioning graft years, which equates to $11.8-21.7 million dialysis cost savings 
(cost per patient per year on dialysis $45,000-$83,000) (Cass, Chadban et al. 2006). Similarly, 
analysis of the SRTR database of 74,998 deceased donor transplants performed between 1990 
and 2002 demonstrated that if older recipients aged 60-64 years received younger donor 
grafts aged 15-50 years, the application of age-matching allocation would have increased 
graft life by 27,500 years, with estimated cost savings in excess of 1 billion dollars (Meier-
Kriesche, Schold et al. 2005). However, at an individual level, the absolute impact of age-
matching appears less impressive. In the ANZDATA study by Lim et al, Younger recipients 
of younger donor kidneys would on average have an additional 3 functioning graft years 
compared to older recipients receiving younger donor kidneys (11.6 vs 8.7 mean graft years 
respectively) and the negative impact of older donor kidneys on functioning graft years 
appears to be greater for younger compared to older recipients (9.3 vs 7.1 mean graft years 
respectively) (Table 4).  
Retrospective analysis of the OPTN database demonstrated that for every 1 year increase in 
donor age, the risk of graft failure (HR 1.01, p<0.001) and death with functioning graft (HR 
1.004, p<0.001) was increased substantially (Moers, Kornmann et al. 2009). The negative 
impact of donor age on graft survival appears maximal between donors aged between 36 to 
40 years (Keith, Demattos et al. 2004). In a simulated age-matching allocation system, the 
reallocation of older donor grafts 65 years from younger recipients <65 years (old-to-
young) to older recipients 65 years (old-to-old) would result in an absolute reduction in 10-
year graft survival by 8% (from 21% to 13%, p<0.001), whereas reallocation of donor kidneys 
<65 years from recipients 65 years (young-to-old) to younger recipients <65 years (young-
to-young) would result in an improvement in 10-year graft survival by 7% (19% to 26%, 
p=0.40). Unlike the ANZDATA study, there was no net benefit of implementing an old-for-
old allocation system with regards to overall functional graft years (Table 4).  
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5.3.2 Kidney allocation score 
In 2004, a subcommittee of the UNOS/OPTN recommended that the establishment of a 
Kidney Allocation Score (KAS) based on Life Years From Transplant (LYFT - measures 
transplant utility), combined with panel reactive antibody (PRA), Donor Profile Index (DPI - 
measures donor quality) and dialysis time (measures transplant equity) could potentially 
lead to an increase in the total number of life years gained from a restricted number of 
available deceased donor kidneys (Wolfe, McCullough et al. 2009; OPTN 2010). LYFT is 
defined as the additional years of life that a potential transplant recipient could expect to 
gain as a consequence of the transplant as compared to not receiving a transplant. LYFT is 
calculated from an equation generated by statistical modeling of historical data combining  
 
 
 
 
Donor/ 
recipient groups 
Graft outcome Patient outcome 
Frei U et al 2008 
ESP/ETKAS^ 
(n=3539) 
 
D/R ≥55 (ESP) 
D ≥65 / R – any age 
D – any age / R 60-64 
5y patient DCGS* 
67% 
67% 
81% 
5y patient survival* 
60% 
71% 
74% 
Lim W et al 2010 
ANZDATA 
(n=4616) 
 
D <60 / R <55 
D <60 / R ≥55 
D ≥60/ R <55 
D ≥60 / R ≥55 
Mean graft years 
11.6 
9.3 
8.7 
7.1 
 
NR 
Keith D et al 2004 
OPTN Registry 
(n=50,322) 
 
D 30-41/ R 0-40 
D 30-41 / R ≥55 
D ≥55 / R 0-40 
D ≥55 / R ≥55 
 
NR 
10y patient survival 
82% 
45% 
76% 
35% 
Moers C et al 2009 
OPTN Registry 
(n=99,860) 
 
D <65 / R <65 
D <65 / R ≥65 
D ≥65/ R <65 
D ≥65 / R ≥65 
10y graft survival 
NR 
19% 
21% 
NR 
DFG 
NR 
56% 
40% 
NR 
Waiser et al 2000 
Single centre 
(n=1269) 
 
D ≤55 / R ≤55 
D ≤55 / R >55 
D >55/ R ≤55 
D >55/ R >55 
8y graft survival* 
50% 
53% 
21% 
57% 
DFG 
11% 
27% 
2% 
26% 
Table 4. Effect of age-matching allocation on graft and patient outcomes. *p<0.05;  
^Prospective data. Abbreviation: ESP – Eurotransplant Senior Program, ETKAS – 
Eurotransplant Kidney Allocation System, ANZDATA – Australia and New Zealand 
Dialysis and Transplant Registry, OPTN – Organ Procurement Transplant Network, D – 
donor, R – recipient, DCGS – death-censored graft survival, DFG – death with functioning 
graft, y – year(s), NR – not reported. Adapted from Lim et al (Nephrol Dial Transplant 
2010). 
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the observed biological effects of patient and donor characteristics on survival. The equation 
created had a C-value of 0.75, that is the equation predicted the potential transplant 
recipients with the longer lifetime 75% of the time, although the equation may be inaccurate 
for the prediction of lifetimes for potential transplant candidates with characteristics that 
differ from the historical group. A C-value of 0.75 is comparable to the model for end-stage 
liver disease (MELD) with a C-value of 0.64, commonly used by many transplanting centres 
to prioritize patients for liver transplantation based on expected survival (Sharma, Schaubel 
et al. 2008). In addition, based on DPI, the kidneys with the longest survival potential will be 
allocated according to the combined score of LYFT (80% of total score) and dialysis 
time/PRA (20% of total score), whereas kidneys with lesser potential for long-term survival 
will be allocated according to dialysis time and PRA, such that better donor kidneys are 
allocated to younger potential recipients, who will have the longest expected LYFT. Older 
potential recipients, who will have a lower expected LYFT and potential recipients with the 
longest dialysis time will be less likely to receive better donor kidneys but may have an 
advantage in being allocated shorter-lived kidneys more rapidly (i.e. shorter waiting-time). 
If deceased donor kidney allocation was based on the KAS, there would a total expected 
increase in LYFT of 2642 years during a single year of allocation as compared with the 
current allocation system in the United States.  
A perception that organ allocation is occurring in an inequitable manner could potentially 
reduce organ donor rates. Nevertheless, the utilization of KAS may improve allocation 
based solely on age-matching, with other patient factors such as diabetes, which are known 
to adversely affect graft and patient survival, are taken into account in the calculation of 
LYFT (Machnicki, Pinsky et al. 2009). 
5.3.3 Positives and negatives of implementing utility-based allocation models 
It remains unclear whether the implementation of utility-based allocation models will 
achieve a better balance between utility and equity. While kidney transplantation is more 
cost effective than dialysis, it will take considerable time for the expected lower long-term 
cost to offset the high initial cost associated with transplantation. In older recipients who are 
more likely to die with a functioning graft, the expense of transplantation may not be 
acceptable, on an economic basis, especially with a high-quality donor kidney.  
Although adoption of an allocation model based on LYFT is likely to increase functioning 
graft years, this model is difficult to implement and may even be perceived as being 
discriminatory to potential ‘high-risk’ potential recipients (e.g. indigenous and highly 
sensitised potential recipients) who will have a higher predicted graft loss, resulting in a 
lower LYFT (Young and Gaston 2000; Young and Gaston 2005). The applicability of LYFT 
based on historical data to more recent eras and patient cohorts, where there may be 
differing clinical practices and use of novel immunosuppressive agents remains uncertain. 
In addition, the optimal weighting of DPI, dialysis time or other factors in the calculation of 
KAS remains undecided. Although not directly considered in the KAS and age-matching 
allocation models, KAS may indirectly take into consideration social equity and possibly 
quality of life, assuming that younger recipients receiving younger donor kidneys will have 
a longer lifespan and therefore greater contribution to society compared to older recipients 
(Laupacis, Keown et al. 1996). In contrast, age-matching allocation is simpler but 
chronological age is often a poor estimate of physiological age and therefore, allocation 
policy based solely on age-matching could potentially disadvantage a number of healthy 
older potential recipients.  
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6. Conclusion 
With the continuing shortage of deceased donor organs coupled with the increased 
utilization of marginal live and deceased donors including ECD and DCD donor kidneys, 
there have been considerable interest in examining the outcomes of these grafts. Over the 
last decade, there has been an expansion of innovative transplant programs, including 
paired exchange and tumour-resected kidney transplant programs, which has helped to 
overcome incompatible transplants and increase donor kidney pool respectively. In this 
chapter, understanding the association between live and deceased donor characteristics and 
transplant outcomes will assist clinicians and potential recipients in the informed process of 
donor selection as well as the prediction of graft outcomes following transplantation.  
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